Abstract: Purpose: The aim of this study was to evaluate amyloid imaging with
11C-PIB PET/CT in the study of cognitive impairment in a clinical setting.
Patients andMethods: The study included 64 patients, with a mean age of
65 years, classified as subjective memory complaints (SMCs; n = 8),
nonamnestic mild cognitive impairment (NA-MCI; n = 10), amnestic MCI
(A-MCI; n = 19), prodromal Alzheimer disease (AD; n = 12), suspicion
of frontotemporal dementia (n = 8), Lewy bodies dementia (DLB; n = 2),
and cortical degeneration (CD; n = 5). Ten healthy controls (HCs), with
a mean age of 59 years, were also included. 11C-PIB was acquired
60 minutes after IV injection of 555 MBq 11C-PIB. Avisual and semiquantitative
analysis was performed.
Results: In HC, 11C-PIB was negative in 9 and positive in 1. Of the
64 patients, 11C-PIB was negative in 27 (42%) and positive in 37 (58%).
11C-PIB was positive in 3 of 8 SMC, in none of 10 NA-MCI, in 14 of 19
A-MCI, in 10 of 12 prodromal AD, in 3 of 8 frontotemporal dementia,
and in the 2 and 5 DLB and CD patients. The semiquantitative results in
terms of mean global SUV ratio were 1.13 for HC, 1.36 for SMC, 1.07
for NA-MCI, 2.01 for A-MCI, 2.37 for prodromal AD, 2.75 for DLB, and
2.44 for CD.
Conclusions: In a clinical setting, 11C-PIB scan had a relevant contribution
on patients with cognitive impairment, excludingADin a high proportion of
MCI patients and differentiating AD from other dementias. In A-MCI,
11C-PIB revealed ß-amyloid deposit in 74%, whereas it was negative in
all NA-MCI patients.
Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria
Fuente: Clinical Nuclear Medicine Volume 41, Number 1, January 2016: e18-23
Fecha de publicación: 01/01/2016
Nº de páginas: 6
Tipo de publicación: Artículo de Revista